Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.49 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506042 | 1.00 | AOC3 (0.49) | AOC3PDE8BPDE10ACNR2GPR119 | |
| SCHEMBL357797 | 0.90 | AOC3 (0.44) | AOC3GPR119OGA | |
| SCHEMBL12525218 | 0.86 | OGA (0.38) | AOC3PDE8BGPR119HDAC6OGA | |
| SCHEMBL24126292 | 0.85 | AOC3 (0.50) | AOC3PDE10ACNR2HDAC6METAP2 | |
| SCHEMBL4281954 | 0.82 | PDE8B (0.40) | AOC3PDE8BGPR119OGAACACB | |
| SCHEMBL4281951 | 0.82 | PDE8B (0.40) | AOC3PDE8BGPR119OGAACACB | |
| SCHEMBL4281963 | 0.82 | PDE8B (0.40) | AOC3PDE8BGPR119OGAACACB | |
| SCHEMBL12503204 | 0.81 | HRH4 (0.47) | AOC3PDE8BGPR119OGA | |
| SCHEMBL13268131 | 0.80 | TRPV1 (0.46) | PDE10AGPR119 | |
| SCHEMBL904092 | 0.78 | PDE8B (0.41) | PDE8BGPR119OGAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853213-B2 | Bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM. CO., LTD (KR) | 2014-10-07 | — | — | US | disclosed |
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM. CO., LTD (KR) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GPR119, GPR65, GPR3 | AOC3 4189/4885PDE8B 1031/4885PDE10A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.